Update on Shareholder Rights Directive II: FCA feedback and final rules on RPTs
Since our note on 23 May, the FCA published its final rules implementing SRD II (on 31 May), ten days before the 10 June 2019 deadline for transposition.
Following feedback to its consultation (CP/7), there are some significant changes to the related party transaction (RPT) rules from those first proposed.
Materiality threshold is 5% for all RPTs
This means that the same threshold that applying to RPTs under LR11 for premium listed issuers is now imposed on all in scope RPTs, but, as originally proposed, the distinction between premium listing and the DTR rules in what is required of issuers in terms of approvals and associated shareholder rights is maintained. Under the revised DTR 7.3, only board approval will be required as well as disclosure, but not shareholder approval and a third party “fair and reasonable” report.
Rest of World (ROW) issuers
ROW (i.e. non-EEA) issuers will have a slightly modified regime. There will be no exemption on the basis that it will in practice not be possible to show that a non-EEA regime provides similar protections in respect of RPTs. But, in order to reduce the compliance burden, ROW issuers will not be subject to the specific board approval rules but will instead be required to announce their material RPTs no later than the date when the terms of the transaction are agreed. ROW issuers will be able to use the definition of “related party” from IFRS or from the alternative accounting standards used in their consolidated annual financial statements, where those accounting standards are deemed “equivalent” for the purposes of the Transparency Directive. This will allow US issuers with a standard listing to use the alternative definition of related party in US GAAP. ROW issuers with a standard or premium listing of equity shares will need to consider whether disclosure of directors’ remuneration is required under the new RPT rules. Remuneration paid to directors may be disclosable if the director is a related party and the transaction is not in the ordinary course of business and concluded on normal market terms. In that case, the ROW issuer will be required to assess the materiality of the transaction and disclose it where the 5% threshold test is met.
Under SRD II, issuers are required to aggregate transactions with the same related party over the previous 12 months. Where the aggregated transactions meet the materiality threshold, board approval and disclosure requirements apply to all of the transactions included in the aggregation and not just the one that triggers the materiality threshold. Unlike LR11, which provides for approval and disclosure of the transaction that triggers the materiality threshold and disclosure of the earlier aggregated transactions, SRD II provides that approval as well as disclosure obligations apply once the materiality threshold is reached. The FCA recognises the challenge for issuers in complying with the provisions for completed transactions including in the aggregation. They note that issuers that are proposing to enter into a sequence of smaller transactions with the same related party will need to take into account and plan for how they will be able to meet their future obligations for those individual transactions under the aggregation rules.
No change to transitional provisions
An issuer is only required to comply with DTR 7.3 and DTR 7 Annex 1 from the start of the financial year beginning on or after 10 June 2019 and only transactions or arrangements entered into on or after the start of the financial year beginning on or after 10 June 2019 must be aggregated. The transitional provision will expire on 31 December 2020.
For more information, please contact Victoria Younghusband.
Phase out of temporary restrictions on use of winding up petitions
Hannah takes a look at the recent UK Government announcement on statutory demands and the presentation of winding up petitions
Preparing your company for sale
We set out here some initial steps to consider in anticipation of a sale.
Overhaul of London's stock market listing regime set to significantly boost capital raising opportunities for founder led UK tech businesses
Charles Russell Speechlys advises discoverIE on its acquisition of Antenova
discoverIE is a leading international designer, manufacturer and supplier of customised electronics to industry.
Charles Russell Speechlys advises Acora on acquisition of Westgate IT
Westgate IT specialises in providing IT support to businesses in the South West.
Charles Russell Speechlys advises Grape Paradise on the acquisition of a fine wine business
Charles Russell Speechlys has advised Grape Paradise on the acquisition of the Sarment Group in the China Mainland territories.
Ongoing supply chain crisis looms large over upcoming allergen law change
The Business Magazine and The Surrey Chambers of Commerce report on the firm's involvement in the sale of Online Fuels Limited to DTN
The firm advised the shareholder management team on the sale of shares in Online Fuels to global data, analytics, and technology group, DTN.
Charles Russell Speechlys advises Appital Ltd on £2.5m Investment led by Frontline Ventures
Appital is an Equity Capital Marketplace which aims to bring innovation to Equity Capital Markets.
The Business Magazine, Insider Media, Business South and The Surrey Chambers of Commerce report on the firm's involvement in Appital's £2.5m growth capital investment
The injection will accelerate the development of Appital’s technology infrastructure, integration with financial institutions.
Healthcare team advises Country Court Care on £57m sale of three care homes
Country Court Care Group Ltd has been active almost 35 years as a nursing and care home operator.
Pei Li Kew
B[re]aking up is never easy... a lesson from the Oetker business split
Charles Russell Speechlys advises Metier on US$39m investment into Africa Mobile Networks
AMN builds, owns, operates and maintains mobile network infrastructure in Africa.
Charles Russell Speechlys advises Apposite Capital on acquisition of i2a Diagnostics
i2a is a leading provider of laboratory instruments, software and reagents for the clinical microbiology market in France.
Brace yourselves: dentists could be liable for actions of self-employed staff
Private companies and public interest – a new approach to corporate governance?
Is now the optimal time to sell your company?
Charles Russell Speechlys advises Duke Royalty on royalty financing agreement with Fairmed Healthcare AG
Duke Royalty is the leading provider of royalty finance to companies in the UK and Europe.
Charles Russell Speechlys shortlisted for Best EIS/SEIS Legal/Regulatory Adviser at 2021 EISA Awards
The Awards denote excellence and recognise the achievements of EIS/SEIS practitioners over the past year.
COVID-19 Vaccination – can an employer make it compulsory for employees?
We review what legal issues to take into account when considering to make vaccination compulsory as an employer.